Gynaecological Considerations in PoTS

The gynaecological impact of PoTS is associated with hypermobile Ehlers Danlos syndrome (hEDS), mast cell activation syndrome (MCAS), histamine intolerance and the influence of female sex hormones. The menstrual cycle plays a key role in changing the cardiovascular environment as well producing inflammatory episodes during menstruation. Women with PoTS have more menstrual irregularities and also suffer from pelvic pain, and vulval inflammatory and pain conditions. Treatment can involve suppressing the menstrual cycle hormonally or using type 1 and 2 histamine receptor blockers or mast cell stabilising medications. There is a higher prevalence of vaginal prolapse which is more challenging to treat due to the association with hypermobile EDS. Access this chapter Tax calculation will be finalised at checkout Purchases are for personal use only Similar content being viewed by others

Shaw BH, Stiles LE, Bourne K, Green EA, Shibao CA, Okamoto LE, et al. The face of postural tachycardia syndrome—insights from a large cross-sectional online community-based survey. J Intern Med. 2019;286(4):438–448. Kavi L, Nuttall M, Low DA, et al. A profile of patients with postural tachycardia syndrome and their experience of healthcare in the UK. Br J Cardiol. 2016;23:1–6. Celletti C, Camerota F, Castori M, et al. Orthostatic intolerance and postural orthostatic tachycardia syndrome in joint hypermobility syndrome/ehlers-danlos syndrome, hypermobility type: neurovegetative dysregulation or autonomic failure? Biomed Res Int. 2017;2017:9161865. De Wandele I, Rombaut L, De Backer T, et al. Orthostatic intolerance and fatigue in the hypermobility type of Ehlers-Danlos syndrome. Rheumatology (Oxford). 2016;55(8):1412–20. De Wandele I, Rombaut L, Leybaert L, et al. Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers-Danlos syndrome. Semin Arthritis Rheum. 2014;44(1):93–100. Hakim A, De Wandele I, O’Callaghan C, Pocinki A, Rowe P. Chronic fatigue in Ehlers-Danlos syndrome-hypermobile type. Am J Med Genet C Semin Med Genet. 2017;175(1):175–80. Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol. 2002;127:147–52. Thieben MJ, Sandroni P, Sletten DM, Benrud-Larson LM, Fealey RD, Vernino S, Lennon VA, Shen WK, Low PA. Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc. 2007;82:308–13. Low PA, Opfer-Gehrking TL, Textor SC, Benarroch EE, Shen WK, Schondorf R, Suarez GA, Rummans TA. Postural tachycardia syndrome (POTS). Neurology. 1995;45(4 Suppl 5):S19–25. Edmonds K, editor. Dewhursts textbook of obstetrics and gynaecology. 8th ed. UK: Wiley-Blackwell; 2012. p. 487–508. Peggs KJ, Nguyen H, Enayat D, Keller NR, Al-Hendy A, Raj SR. Gynecologic disorders and menstrual cycle lightheadedness in postural tachycardia syndrome. Int J Gynaecol Obstet. 2012;118(3):242–6. Fu Q, VanGundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD. Menstrual cycle affects renal-adrenal and hemodynamic responses during prolonged standing in the postural orthostatic tachycardia syndrome. Hypertension. 2010;56(1):82–90. Mar PL, Raj SR. Neuronal and hormonal perturbations in postural tachycardia syndrome [published correction appears in Front Physiol. 2019;10:978]. Front Physiol. 2014;5:220. Published 2014 Jun 16. Garland EM, Celedonio JE, Raj SR. Postural tachycardia syndrome: beyond orthostatic intolerance. Curr Neurol Neurosci Rep. 2015;15(9):60. Hilliard LM, Sampson AK, Brown RD, Denton KM. The “his and hers” of the renin-angiotensin system. Curr Hypertens Rep. 2013;15(1):71–9. Kaschina E, Namsolleck P, Unger T. AT2 receptors in cardiovascular and renal diseases. Pharmacol Res. 2017;125(Pt A):39–47. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 1996;61(4):166–71. Fu Q. Microneurographic research in women. Front Physiol. 2012;3:278. Stickford AS, VanGundy TB, Levine BD, Fu Q. Menstrual cycle phase does not affect sympathetic neural activity in women with postural orthostatic tachycardia syndrome. J Physiol. 2015;593(9):2131–43. Ray CA, Carter JR. Vestibular activation of sympathetic nerve activity. Acta Physiol Scand. 2003;177(3):313–9. Temkin SM, Minasian L, Noone AM. The end of the hysterectomy epidemic and endometrial cancer incidence: what are the unintended consequences of declining hysterectomy rates? Front Oncol. 2016;6:89. Odutayo A, Cherney D, Miller J, et al. Transdermal contraception and the renin-angiotensin-aldosterone system in premenopausal women. Am J Physiol Renal Physiol. 2015;308(6):F535–40. Drudy L, Sheppard B, Bonnar J. Mast cells in the normal uterus and in dysfunctional uterine bleeding. Eur J Obstet Gynecol Reproduct Biol. 1991;39:193–201. Salamonsen LA, Woolley DE. Menstruation: induction by matrix metalloproteinases and inflammatory cells. J Reprod Immunol. 1999;44(1–2):1–27. Shibao C, Arzubiaga C, Roberts LJ, Raj S, Black B, Harris P, Biaggioni I. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45:385–90. Simpson G. Menstrual anaphylactoid reactions and presumed systemic mast cell activation syndrome. Intern Med J. 2016;46(7):858–9. Stachenfeld NS. Sex hormone effects on body fluid regulation. Exerc Sport Sci Rev. 2008;36(3):152–9. Castori M, Morlino S, Dordoni C, et al. Gynecologic and obstetric implications of the joint hypermobility syndrome (a.k.a. Ehlers-Danlos syndrome hypermobility type) in 82 Italian patients. Am J Med Genet A. 2012;158A(9):2176–82. Sorokin Y, Johnson MP, Rogowski N, Richardson DA, Evans MI. Obstetric and gynecologic dysfunction in the Ehlers-Danlos syndrome. J Reprod Med. 1994;39(4):281–4. Hurst BS, Lange SS, Kullstam SM, et al. Obstetric and gynecologic challenges in women with Ehlers-Danlos syndrome. Obstet Gynecol. 2014;123(3):506–13. Hugon-Rodin J, Lebègue G, Becourt S, Hamonet C, Gompel A. Gynecologic symptoms and the influence on reproductive life in 386 women with hypermobility type Ehlers-Danlos syndrome: a cohort study. Orphanet J Rare Dis. 2016;11(1):124. Afrin L, Dempsey T, Rosenthal L, Dorff S. Successful mast-cell-targeted treatment of chronic dyspareunia, vaginitis, and dysfunctional uterine bleeding. J Obstet Gynaecol. 2019;39(5):664–9. Jia X, Rana N, Crouss T, Whitmore KE. Gynecological associated disorders and management. Int J Urol. 2019;26(Suppl 1):46–51. Afrin LB, Molderings GJ. A concise, practical guide to diagnostic assessment for mast cell activation disease. World J Hematol. 2014;3:1–17. Sun Y, Harlow BL. The association of vulvar pain and urological urgency and frequency: findings from a community-based case-control study. Int Urogynecol J. 2019;30(11):1871–8. Krapf JM, Goldstein A. Two case presentations of profound labial edema as a presenting symptom of hypermobility-type Ehlers-Danlos syndrome. J Sex Med. 2013;10(9):2347–50. Wells R, Tonkin A. Clinical approach to autonomic dysfunction [published correction appears. [Intern Med J. 2017;47(1):126]. Intern Med J. 2016;46(10):1134–39. Izquierdo-Casas J, Comas-Baste O, Latorre-Moratalla ML, Lorente-Gascon M, Duelo A, Soler-Singla L, Vidal-Carou. Low serum diamine oxidase (DAO) activity levels in patients with migraine. J Physiol Biochem. 2018;74:93–9. Mušič E, Korošec P, Šilar M, Adamič K, Košnik M, Rijavec M. Serum diamine oxidase activity as a diagnostic test for histamine intolerance. Wien Klin Wochenschr. 2013;125:239–43. Manzotti G, Breda D, Di Gioacchino M, Burastero SE. Serum diamine oxidase activity in patients with histamine intolerance. Int J Immunopathol Pharmacol. 2016;29(1):105–11. Nurmatov UB, Rhatigan E, Simons FE, Sheikh A. H1-antihistamines for primary mast cell activation syndromes: a systematic review. Allergy. 2015;70(9):1052–61. Doherty TA, White AA. Postural orthostatic tachycardia syndrome and the potential role of mast cell activation. Auton Neurosci. 2018;215:83–8. https://bnf.nice.org.uk/drug/sodium-cromoglicate.html#indicationsAndDoses. Zhu TH, Zou G, Ding SJ, Li TT, Zhu LB, Wang JZ, et al. Mast cell stabilizer ketotifen reduces hyperalgesia in a rodent model of surgically induced endometriosis. J Pain Res. 2019;29(12):1359–69. Barber MD, Maher C. Epidemiology and outcome assessment of pelvic organ prolapse. Int Urogynecol J. 2013;24(11):1783–90. Veit-Rubin N, Cartwright R, Singh AU, Digesu GA, Fernando R, Khullar V. Association between joint hypermobility and pelvic organ prolapse in women: a systematic review and meta-analysis. Int Urogynecol J. 2016;27(10):1469–78. Mastoroudes H, Giarenis I, Cardozo L, et al. Lower urinary tract symptoms in women with benign joint hypermobility syndrome: a case-control study. Int Urogynecol J. 2013;24(9):1553–8. Chen B, Yeh J. Alterations in connective tissue metabolism in stress incontinence and prolapse. J Urol. 2011;186:1768–72. Knuuti E, Kauppila S, Kotila V, Risteli J, Nissi R. Genitourinary prolapse and joint hypermobility are associated with altered type I and III collagen metabolism. Arch Gynecol Obstet. 2011;283(5):1081–5. Author information Authors and Affiliations Corresponding author Editor information Editors and Affiliations Rights and permissions Copyright information © 2021 Springer Nature Switzerland AG About this chapter Cite this chapter Tailor, V., Khullar, V. (2021). Gynaecological Considerations in PoTS. In: Gall, N., Kavi, L., Lobo, M.D. (eds) Postural Tachycardia Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-030-54165-1_18 Download citation DOI: https://doi.org/10.1007/978-3-030-54165-1_18 Published: Publisher Name: Springer, Cham Print ISBN: 978-3-030-54164-4 Online ISBN: 978-3-030-54165-1 eBook Packages: MedicineMedicine (R0)